Literature DB >> 19244003

The role of surgery in the management of congenital melanocytic naevi in children: a perspective from Great Ormond Street Hospital.

Veronica Kinsler1, Neil Bulstrode.   

Abstract

Recent advances in research have prompted this review of the role of surgery in the management of congenital melanocytic naevi (CMNs). Good data on the incidence of neurological and malignant complications of CMNs have re-fuelled the debates on whether surgery decreases the risk of malignant melanoma and whether early surgery is advantageous. We conclude the following: 1) untreated CMNs can lighten spontaneously, sometimes dramatically, 2) routine surgery has not been demonstrated to reduce the risk of malignancy and is, therefore, for cosmetic reasons only, 3) early surgery has not been shown to be advantageous and carries increased anaesthetic risk and 4) there is some evidence that surgical intervention may adversely affect the behaviour of the CMN cells. Our current practice is based on the following guidelines: 1) patients are treated in a multidisciplinary-team setting which includes the specialties of paediatric dermatology, plastic surgery and neuroradiology with access to neurology, neurosurgery and oncology, 2) serial photographs are taken at yearly intervals to assess spontaneous lightening. 3) all routine surgery is delayed for at least the first year. 4) patients with facial CMNs (either the principal lesion or large satellites) are offered surgery for cosmetic reasons, 5) patients with a single, easily excisable CMN are offered surgery for cosmetic reasons and 6) all families are made aware of the possibility of spontaneous lightening and the possibility that surgery may have effects on the behaviour of naevus cells.

Entities:  

Mesh:

Year:  2009        PMID: 19244003     DOI: 10.1016/j.bjps.2008.12.016

Source DB:  PubMed          Journal:  J Plast Reconstr Aesthet Surg        ISSN: 1748-6815            Impact factor:   2.740


  8 in total

1.  [Congenital nevi in childhood].

Authors:  R Wälchli; M Theiler; K Neuhaus; L Weibel
Journal:  Hautarzt       Date:  2013-01       Impact factor: 0.751

2.  Giant congenital melanocytic nevi: selected aspects of diagnostics and treatment.

Authors:  Ewa Sawicka; Orest Szczygielski; Klaudia Żak; Paweł Pęczkowski; Elżbieta Michalak; Monika Bekiesińska-Figatowska
Journal:  Med Sci Monit       Date:  2015-01-11

3.  Melanin pigments in the melanocytic nevus regress spontaneously after inactivation by high hydrostatic pressure.

Authors:  Michiharu Sakamoto; Naoki Morimoto; Chizuru Jinno; Atsushi Mahara; Shuichi Ogino; Shigehiko Suzuki; Kenji Kusumoto; Tetsuji Yamaoka
Journal:  PLoS One       Date:  2017-11-01       Impact factor: 3.240

4.  A prospective study of patients with large congenital melanocytic nevi and the risk of melanoma.

Authors:  Ana Carolina Leite Viana; Eugênio Marcos Andrade Goulart; Bernardo Gontijo; Flávia Vasques Bittencourt
Journal:  An Bras Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.896

5.  Final congenital melanocytic naevi colour is determined by normal skin colour and unaltered by superficial removal techniques: a longitudinal study.

Authors:  S Polubothu; V A Kinsler
Journal:  Br J Dermatol       Date:  2019-08-07       Impact factor: 9.302

6.  Extraordinary Large Giant Congenital Melanocytic Nevus Treated with Integra Dermal Regeneration Template.

Authors:  Kim A Tønseth; Charles Filip; Robert Hermann; Harald Vindenes; Hans Erik Høgevold
Journal:  Plast Reconstr Surg Glob Open       Date:  2015-08-10

Review 7.  Giant congenital melanocytic nevus.

Authors:  Ana Carolina Leite Viana; Bernardo Gontijo; Flávia Vasques Bittencourt
Journal:  An Bras Dermatol       Date:  2013 Nov-Dec       Impact factor: 1.896

8.  Germline melanocortin-1-receptor genotype is associated with severity of cutaneous phenotype in congenital melanocytic nevi: a role for MC1R in human fetal development.

Authors:  Veronica A Kinsler; Sayeda Abu-Amero; Peter Budd; Ian J Jackson; Susan M Ring; Kate Northstone; David J Atherton; Neil W Bulstrode; Philip Stanier; Raoul C Hennekam; Neil J Sebire; Gudrun E Moore; Eugene Healy
Journal:  J Invest Dermatol       Date:  2012-05-10       Impact factor: 8.551

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.